ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zheng, Yu Zhu ^a,b   Ma, Rui ^a   Zhou, Jian Kang ^a   Guo, Cheng Lin ^a   Wang, Yong Sheng ^a   Li, Zheng Guang ^a   Liu, Lun Xu ^a   Peng, Yong ^a  

^a SICHUAN UNIVERSITY   (China)

^b Third People's Hospital of Chengdu   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEX FACTOR; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SEX FACTORS;

EID: 84994860547     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36447     Document Type: Article

References (37)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA. Cancer. J. Clin. 66, 7-30 (2016).
2. Lewis, D. R., Check, D. P., Caporaso, N. E., Travis, W. D. & Devesa, S. S. US lung cancer trends by histologic type. Cancer 120, 2883-2892 (2014).
3. Li, J. et al. Identification of high-quality cancer prognostic markers and metastasis network modules. Nat Commun. 1, 1-8 (2010).
4. Sung, H. J. & Cho, J. Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB. Rep. 41, 615-625 (2008).
5. van Rens, M. T., de la Riviere, A. B., Elbers, H. R. & van Den Bosch, J. M. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II and IIIA. Chest. 117, 374-379 (2000).
6. Spira, A. & Ettinger, D. S. Multidisciplinary management of lung cancer. N. Engl. J. Med. 350, 379-392 (2004).
7. Farhat, F. S. & Houhou, W. Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther. Adv. Med. Oncol. 5, 249-270 (2013).
8. Beau-Faller, M. et al. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10117 patients: a multicenter observational study by the French ERMETIC-IFCT network. Ann. Oncol. 25, 126-131 (2014).
9. Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
10. Tan, C. S., Gilligan, D. & Pacey, S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 16, e447-e459 (2015).
11. Santos, E. et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661-664 (1984).
12. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
13. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 30, 863-870 (2012).
14. Cadranel, J., Ruppert, A. M., Beau-Faller, M. & Wislez, M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Crit Rev. Oncol. Hematol. 88, 477-493 (2013).
15. Hojjat-Farsangi, M. et al. The receptor tyrosine kinase ROR1-an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 29, 21-31 (2014).
16. Yamaguchi, T. et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 21, 348-361 (2012).
17. Zhang, S. et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7, e31127 (2012).
18. Zhang, S. et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 181, 1903-1910 (2012).
19. Zhang, H. et al. ROR1 expression correlated with poor clinical outcome in human ovarian cancer. Sci Rep. 4, 5811 (2014).
20. Tan, H. et al. miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer. Int J Oncol. 48, 181-190 (2016).
21. Cui, B. et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res. 73, 3649-3660 (2013).
22. Liu, Y. et al. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma. PLoS One 10, e0127092 (2015).
23. Yu, J. et al. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. J. Clin. Invest. 126(2), 585-598 (2016).
24. DeSantis, C. E. et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 64, 252-271 (2014).
25. Peng, L., Song, Z. G. & Jiao, S. C. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep. 4, 6104 (2014).
26. Remon, J. et al. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. Cancer Treat Rev. 40, 723-729 (2014).
27. Hrustanovic, G., Lee, B. J. & Bivona, T. G. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 14, 304-314 (2013).
28. Borcherding, N., Kusner, D., Liu, G. H. & Zhang, W. ROR1, an embryonic protein with an emerging role in cancer biology. Protein Cell 5, 496-502 (2014).
29. Baskar, S. et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 14, 396-404 (2008).
30. Bicocca, V. T. et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22, 656-667 (2012).
31. Rabbani, H. et al. Expression of ROR1 in patients with renal cancer-a potential diagnostic marker. Iran Biomed J. 14, 77-82 (2010).
32. Hojjat-Farsangi, M. et al. Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells. PLoS. One 8, e61167 (2013).
33. Mellstedt, H. et al. A new class of anti-cancer drugs targeting the tyrosine kinase receptor ROR1 in CLL. J Clin Oncol. 33 (suppl.), Abstract NO: 8556 (2015).
34. Mellstedt, H. et al. A new class of compound for pancreatic carcinoma targeting the tyrosine kinase receptor (TKR) ROR1. J Clin Oncol. 32 (suppl.), Abstract NO: e13561 (2014).
35. Choi, M. Y. et al. Pre-clinical specificity and safety of UC-961, a first-In-Class monoclonal antibody targeting ROR1. Clin Lymphoma Myeloma Leuk. 15, S167-S169 (2015).
36. Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 19, 3153-3164 (2013).
37. Karachaliou, N. et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. Transl Lung Cancer Res. 3, 122-130 (2014).